Evidence map›Paper›PMID 35595963›Full record

ArticleJournal of clinical laboratory analysis2022

Analytical performances of a glycated albumin assay that is traceable to standard reference materials and reference range determination.

Xinran Tao, Ryosuke Koguma, Yoko Nagai, Takuji Kohzuma

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.The Journal of clinical endocrinology and metabolism · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xinran TaoDiagnostics Department, Asahi Kasei Pharma Corporation, IVD Kit Product Group, Yurakucho, Japan.ORCID https://orcid.org/0000-0002-9178-2778
Ryosuke KogumaDiagnostics Department, Asahi Kasei Pharma Corporation, IVD Kit Product Group, Yurakucho, Japan.
Yoko NagaiDiagnostics Department, Asahi Kasei Pharma Corporation, IVD Kit Product Group, Yurakucho, Japan.
Takuji KohzumaDiagnostics Department, Asahi Kasei Pharma Corporation, IVD Kit Product Group, Yurakucho, Japan.
Asahi Kasei (Japan) · JP

Funding

Asahi Kasei Pharma Corporation
6 · The paper itself

Abstract

backgroundGlycated albumin (GA) is an intermediate-term marker for monitoring glycemic control (preceding 2-3 weeks) in patients with diabetes mellitus. We evaluated the performance of Lucica Glycated Albumin-L, a new GA assay that is traceable to standard reference materials and determined the reference range in healthy subjects without diabetes.

methodsThe performance and reference range studies were conducted in accordance with Clinical and Laboratory Standards Institute (CLSI) Guidelines. The traceability was established using reference material recommended by the Japan Society of Clinical Chemistry (JSCC).

resultsThe coefficient of variation (CV) of overall repeatability, within-laboratory precision, and overall reproducibility values of GA values were not more than 2.6%, 3.3%, and 1.6%, respectively, among laboratories. The GA values showed good linearity from 173 to 979 mmol/mol (9.4%-54.9%) across the assay range. The GA reference range in 262 healthy subjects was between 183 and 259 mmol/mol (9.9%-14.2%) while that of subjects with diabetes was 217-585 mmol/mol (11.8-32.6%). The reagent was stable for 2 months on the bench at room temperature. The limits of blank, detection, and qualification were 6.9, 7.9, and 9.7 μmol/L for GA concentration, and 3.8, 7.0, and 21.8 μmol/L for albumin concentration, respectively. Hemoglobin slightly affected the assay, while other classical interfering substances had no significant impact.

conclusionsThe present GA assay shows comparable performance to current clinical assays and could be used for intermediate-term monitoring of glycemic control in diabetes patients.

Indexed as

Diabetes MellitusGlycation End Products, AdvancedBlood GlucoseGlycated HemoglobinGlycated Serum AlbuminHumansReference ValuesReproducibility of ResultsSerum AlbuminBlood GlucoseGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedSerum Albuminanalytical performancediabetes mellitusglycated albuminobserved valuereference rangestandard reference materials

Identifiers

PMID35595963
PMCPMC9280011
OpenAlexW4281257077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.